Oxifun1%

Oxifun is a topical (skin-applied) antifungal medicine used to treat certain fungal skin infections.

Established / FDA-approved uses

• Tinea pedis (athlete's foot)
• Tinea cruris (jock itch)
• Tinea corporis (ringworm of the body)
• Cutaneous candidiasis (skin infection caused by Candida yeast)

Other supported use

• Tinea (pityriasis) versicolor — a superficial fungal skin infection caused by Malassezia species; some Oxifun cream formulations are also labeled for this indication.

Oxifun is not intended for infections of the nails, scalp, eyes, mouth, or vagina.

Each formulation of Oxiconazole typically contains Oxiconazole nitrate as the active ingredient, most commonly as a 1% w/w topical cream or lotion. Inactive ingredients (bases, emulsifiers, preservatives) vary by manufacturer and formulation.

Oxifun is a synthetic imidazole-derivative antifungal agent formulated for topical (on-the-skin) use. It is applied directly to the affected area of skin to treat superficial fungal infections caused by dermatophytes and yeasts.

Oxifun is available as a topical cream and lotion and is intended for external use only.

Oxifun belongs to the topical antifungal therapeutic class, specifically the imidazole group of antifungal agents.

Mechanism of action: Oxiconazole is an imidazole antifungal that inhibits the cytochrome P450-dependent enzyme 14-α-demethylase, which is required for conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane.

By blocking ergosterol synthesis, Oxiconazole disrupts fungal cell membrane structure and function, leading to increased membrane permeability, leakage of cellular contents, and inhibition of fungal cell growth and replication. Depending on concentration and organism, Oxiconazole can be fungistatic or fungicidal against susceptible dermatophytes (Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum) and yeasts (Candida albicans, Malassezia furfur).

Pharmacokinetics: Systemic absorption of Oxiconazole through intact skin after topical application is minimal, which limits systemic pharmacologic and toxicologic effects.

Oxifun is for topical (skin) use only. Wash and dry the affected area, then apply a thin layer of cream or lotion to cover the affected skin and a small margin of surrounding healthy skin. Wash hands after application unless the hands are the area being treated. Avoid occlusive dressings unless directed by a physician.

Because Oxifun is applied topically and has minimal systemic absorption through intact skin, clinically significant drug-drug interactions are not well established.

As a general precaution, avoid simultaneous use of other topical products (including other antifungals, corticosteroids, or irritant skin preparations) on the same skin area unless directed by a physician, since this may alter local skin tolerance or effectiveness.

Oxifun is generally well tolerated when used as directed. The most commonly reported side effects are local reactions at the site of application, including:

• Burning or stinging sensation
• Itching
• Redness (erythema) or irritation
• Skin peeling or dryness
• Rash

These effects are usually mild and transient. Rarely, an allergic contact dermatitis reaction can occur (see Contraindications). If severe irritation, blistering, or signs of an allergic reaction develop, discontinue use and seek medical advice.

Pregnancy: There are no adequate and well-controlled studies of Oxifun in pregnant women. Because systemic absorption after topical use is minimal, risk to the fetus is expected to be low, but Oxifun should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk; consult a physician before use.

Lactation: It is not known whether topically applied Oxifun passes into breast milk in clinically significant amounts. Caution is advised, and breastfeeding mothers should avoid applying Oxifun directly to the breast/nipple area or consult a physician before use.

Oxifun is for external use only. Avoid contact with the eyes, inside of the nose or mouth, and other mucous membranes; if accidental contact occurs, rinse thoroughly with water.

• If irritation, burning, or sensitivity worsens or does not improve, discontinue use and consult a physician.
• Complete the full prescribed course of treatment even if symptoms improve early, to reduce the risk of recurrence (see Dosage and Administration).
• If there is no improvement after the recommended treatment duration, or symptoms worsen, seek medical evaluation, as the diagnosis may need to be reconfirmed or alternative therapy considered.
• Do not use Oxifun on broken, infected (bacterial), or severely inflamed skin unless directed by a physician.
• Keep out of reach of children.

Oxifun is intended for topical use, and significant systemic toxicity from accidental topical overdose is unlikely due to minimal skin absorption. Excessive or prolonged application may increase the likelihood of local skin irritation.

If Oxifun is accidentally ingested (swallowed) or if a large amount is applied and systemic symptoms are suspected, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Safety and effectiveness of Oxifun in pediatric patients below the studied age range have not been formally established in all cases. When used in children, it should be under medical supervision, applied sparingly, and only for the labeled duration.

Geriatric use

No specific dose adjustment is generally required in elderly patients using topical Oxifun, as systemic absorption is minimal; general precautions for topical antifungal use apply.

Renal/hepatic impairment

Because systemic absorption of topically applied Oxifun is minimal, no specific dose adjustment is established or generally required for renal or hepatic impairment.

Duration of Oxifun treatment depends on the infection being treated: typically about 2 weeks for tinea corporis, tinea cruris, cutaneous candidiasis, and tinea versicolor, and up to 4 weeks for tinea pedis. The full course should be completed even if symptoms resolve earlier, to reduce recurrence risk (see Dosage and Administration).

Oxiconazole belongs to the imidazole antifungal class of medicines, used topically for dermatophyte and yeast skin infections.

Oxiconazole works by inhibiting fungal ergosterol synthesis through blockade of the cytochrome P450-dependent 14-α-demethylase enzyme. This disrupts the fungal cell membrane, increasing its permeability and ultimately inhibiting growth of, or killing, susceptible dermatophytes and yeasts.

Safety and effectiveness of Oxifun in pediatric patients have not been formally established across all age groups. Use in children should be guided by a physician, applied only to the affected area, for the shortest effective duration, with close monitoring for local irritation.